{ "run": { "id": "cmnr141du0466p6583cym5l7c", "region": "US", "assetId": "cmnr141d4045yp658aa1xmue8", "ticker": "HCA", "snapshotId": "cmnr141df0462p658r4m42zgz", "promptTemplateId": "cmnqt07si0005lm3jzpxuu1ux", "createdAt": "2026-04-09T05:20:58.623Z", "promptTemplate": { "id": "cmnqt07si0005lm3jzpxuu1ux", "name": "Oficial 08.apr.2026", "version": 1 }, "snapshot": { "id": "cmnr141df0462p658r4m42zgz", "assetId": "cmnr141d4045yp658aa1xmue8", "asOf": "2026-04-08T20:00:02.000Z", "snapshot": { "asOf": "2026-04-08T20:00:02.000Z", "quote": { "asOf": "2026-04-08T20:00:02.000Z", "open": null, "price": 505.12, "dayLow": 494.791, "volume": 751681, "dayHigh": 506.31, "currency": "USD", "prevClose": 489.58, "week52Low": 314.43, "week52High": 556.52 }, "fundamentals": { "pe": 16.2668989547038, "beta": 0.710815368722641, "epsTTM": 28.7, "fcfTTM": 7386000000, "growth": { "epsYoy": 0.2887292321508756, "revenueYoy": 0.07077602934719487 }, "sector": "Services-General Medical & Surgical Hospitals, NEC", "margins": { "net": 0.08973544973544974, "gross": null, "operating": null }, "website": "https://hcahealthcare.com/", "industry": "Healthcare", "pegRatio": 0.563396329271002, "ebitdaTTM": 14295000000, "forwardPe": 15.4180977542933, "marketCap": 63269000000, "totalCash": 621000000, "totalDebt": 33867000000, "debtEquity": -8.15895138543222, "quickRatio": 1.050406084826608, "revenueTTM": 75600000000, "companyName": "HCA Healthcare, Inc.", "priceToBook": 2.48753151183232, "currentRatio": 1.443341498001805, "dividendYield": 0.00619723666923877, "returnOnAssets": 0.1505614985130277, "returnOnEquity": -1.12560146009623, "analystOpinions": null, "businessSummary": "HCA Healthcare, Inc. (historically known as Hospital Corporation of America) is an American global for-profit operator of health care facilities that was founded in 1968. It is based in Nashville, Tennessee, and, as of May 2020, owned and operated 186 hospitals and approximately 2,400 sites of care, including surgery centers, freestanding emergency rooms, urgent care centers and physician clinics in 20 states and the United Kingdom. As of 2024, HCA Healthcare is ranked #61 on the Fortune 500 rankings of the largest United States corporations by total revenue. In the 1990s, the company engaged in illegal accounting and other crimes that resulted in the payment of more than $2 billion in federal fines and other penalties, and the dismissal of the CEO Rick Scott by the board of directors.", "enterpriseValue": 158505773180, "analystTargetLow": null, "analystTargetHigh": null, "analystTargetMean": null, "fullTimeEmployees": 316000, "sharesOutstanding": 223622200, "enterpriseToEbitda": 11.08819679468345, "analystTargetMedian": null, "enterpriseToRevenue": 2.096637211375661, "operatingCashflowTTM": 12636000000, "analystRecommendationKey": null } }, "createdAt": "2026-04-09T05:20:58.611Z" }, "results": [ { "id": "cmnr141dy046ap658zbmwc32b", "runId": "cmnr141du0466p6583cym5l7c", "modelId": "anthropic", "status": "SUCCESS", "rawOutput": "{\"model\":\"ai-equity-research-v1\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"HCA\",\"currency\":\"USD\",\"current_price\":505.12,\"target_price_6m\":530,\"target_price_12m\":555,\"recommendation\":\"BUY\",\"confidence\":0.67,\"thesis_bullets\":[\"Largest US for-profit hospital operator with durable scale advantages\",\"Forward P/E of ~15.4x and PEG of 0.56 signal attractive valuation\",\"EPS grew ~29% YoY driven by volume recovery and cost discipline\",\"High leverage (negative equity) constrains flexibility but funds buybacks\",\"Aging US population provides structural tailwind to hospital admissions\"],\"key_drivers\":[{\"driver\":\"Same-store admissions and revenue per admission growth\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Aging demographics increasing healthcare utilization\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Share buyback program reducing float and boosting EPS\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Operational efficiency gains across 186-hospital network\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Medicaid redetermination and payer mix shifts\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"High absolute debt load ($33.9B) increases interest expense risk\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Labor cost inflation for nurses and clinical staff\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Potential federal healthcare policy or reimbursement changes\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Significant leverage with negative book equity amplifies downside in a downturn\",\"Reimbursement rate cuts from Medicare/Medicaid programs\",\"Persistent labor shortages driving wage inflation above revenue growth\",\"Regulatory or antitrust scrutiny on hospital consolidation\",\"Rising uncompensated care if economy weakens and uninsured population grows\"],\"assumptions\":{\"revenue_cagr_3y\":0.06,\"ebit_margin_target\":0.17,\"wacc\":0.085,\"terminal_multiple\":16.0},\"scenarios\":{\"bear\":{\"target_price\":420,\"prob\":0.20,\"notes\":\"Margin compression from labor costs and volume softness; multiple contracts to ~14x.\"},\"base\":{\"target_price\":555,\"prob\":0.55,\"notes\":\"Mid-single-digit revenue growth, stable margins, P/E sustained near 16-17x on ~$34 EPS.\"},\"bull\":{\"target_price\":635,\"prob\":0.25,\"notes\":\"Accelerating volumes, favorable payer mix, aggressive buybacks push EPS above $35; multiple re-rates to 18x.\"}},\"method_notes\":\"Earnings-power valuation anchored on forward EPS (~$33-35) with P/E range of 14-18x. Base assumes 6% revenue CAGR, ~17% EBIT margin, and 16x terminal P/E. PEG of 0.56 supportive but offset by high leverage risk and policy uncertainty. 12M base target of $555 implies ~9.9% upside, consistent with BUY. Probability-weighted scenario value ~$544. Not investment advice.\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "ai-equity-research-v1", "risks": [ "Significant leverage with negative book equity amplifies downside in a downturn", "Reimbursement rate cuts from Medicare/Medicaid programs", "Persistent labor shortages driving wage inflation above revenue growth", "Regulatory or antitrust scrutiny on hospital consolidation", "Rising uncompensated care if economy weakens and uninsured population grows" ], "ticker": "HCA", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Mid-single-digit revenue growth, stable margins, P/E sustained near 16-17x on ~$34 EPS.", "target_price": 555 }, "bear": { "prob": 0.2, "notes": "Margin compression from labor costs and volume softness; multiple contracts to ~14x.", "target_price": 420 }, "bull": { "prob": 0.25, "notes": "Accelerating volumes, favorable payer mix, aggressive buybacks push EPS above $35; multiple re-rates to 18x.", "target_price": 635 } }, "confidence": 0.67, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.06, "terminal_multiple": 16, "ebit_margin_target": 0.17 }, "key_drivers": [ { "driver": "Same-store admissions and revenue per admission growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Aging demographics increasing healthcare utilization", "impact": "HIGH", "direction": "POS" }, { "driver": "Share buyback program reducing float and boosting EPS", "impact": "MED", "direction": "POS" }, { "driver": "Operational efficiency gains across 186-hospital network", "impact": "MED", "direction": "POS" }, { "driver": "Medicaid redetermination and payer mix shifts", "impact": "MED", "direction": "NEG" }, { "driver": "High absolute debt load ($33.9B) increases interest expense risk", "impact": "HIGH", "direction": "NEG" }, { "driver": "Labor cost inflation for nurses and clinical staff", "impact": "MED", "direction": "NEG" }, { "driver": "Potential federal healthcare policy or reimbursement changes", "impact": "MED", "direction": "NEG" } ], "method_notes": "Earnings-power valuation anchored on forward EPS (~$33-35) with P/E range of 14-18x. Base assumes 6% revenue CAGR, ~17% EBIT margin, and 16x terminal P/E. PEG of 0.56 supportive but offset by high leverage risk and policy uncertainty. 12M base target of $555 implies ~9.9% upside, consistent with BUY. Probability-weighted scenario value ~$544. Not investment advice.", "current_price": 505.12, "recommendation": "BUY", "thesis_bullets": [ "Largest US for-profit hospital operator with durable scale advantages", "Forward P/E of ~15.4x and PEG of 0.56 signal attractive valuation", "EPS grew ~29% YoY driven by volume recovery and cost discipline", "High leverage (negative equity) constrains flexibility but funds buybacks", "Aging US population provides structural tailwind to hospital admissions" ], "target_price_6m": 530, "target_price_12m": 555 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "anthropic", "webSearch": { "enabled": false, "maxToolCalls": 2, "disabledReason": null }, "pauseTurns": 0, "stopReason": "end_turn" }, "sanityIssues": [] }, "latencyMs": 35988, "createdAt": "2026-04-09T05:20:58.623Z", "usage": { "inputTokens": 3686, "outputTokens": 1611, "costUsd": 0.058705 } }, { "id": "cmnr141dy046dp658nfsxszmg", "runId": "cmnr141du0466p6583cym5l7c", "modelId": "deepseek.reasoner", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"AI Equity Research Model v1\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"HCA\",\n \"currency\": \"USD\",\n \"current_price\": 505.12,\n \"target_price_6m\": 520.0,\n \"target_price_12m\": 550.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.65,\n \"thesis_bullets\": [\n \"Strong EPS growth from operational efficiencies.\",\n \"Stable healthcare demand supports revenue growth.\",\n \"Low PEG ratio indicates attractive valuation.\",\n \"High debt offset by robust cash flow generation.\",\n \"Regulatory risks mitigated by strong market position.\"\n ],\n \"key_drivers\": [\n {\"driver\": \"EPS Growth\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n {\"driver\": \"Revenue Growth\", \"impact\": \"MED\", \"direction\": \"POS\"},\n {\"driver\": \"Healthcare Demand\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n {\"driver\": \"Regulatory Changes\", \"impact\": \"HIGH\", \"direction\": \"NEG\"},\n {\"driver\": \"Debt Levels\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n {\"driver\": \"Operational Efficiency\", \"impact\": \"HIGH\", \"direction\": \"POS\"},\n {\"driver\": \"Competition\", \"impact\": \"MED\", \"direction\": \"NEG\"},\n {\"driver\": \"Economic Conditions\", \"impact\": \"LOW\", \"direction\": \"NEG\"}\n ],\n \"risks\": [\n \"Regulatory changes impacting reimbursement rates\",\n \"Increased competition from healthcare providers\",\n \"Economic downturn reducing patient volumes\",\n \"High leverage increasing interest rate sensitivity\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.07,\n \"ebit_margin_target\": 0.18,\n \"wacc\": 0.08,\n \"terminal_multiple\": 11.0\n },\n \"scenarios\": {\n \"bear\": {\"target_price\": 480.0, \"prob\": 0.3, \"notes\": \"Regulatory headwinds and slower growth materialize.\"},\n \"base\": {\"target_price\": 550.0, \"prob\": 0.5, \"notes\": \"Steady execution with moderate upside as expected.\"},\n \"bull\": {\"target_price\": 600.0, \"prob\": 0.2, \"notes\": \"Strong operational improvements drive market share gains.\"}\n },\n \"method_notes\": \"DCF and multiples analysis using historical data. BUY due to 9% 12M expected return with balanced risks. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "AI Equity Research Model v1", "risks": [ "Regulatory changes impacting reimbursement rates", "Increased competition from healthcare providers", "Economic downturn reducing patient volumes", "High leverage increasing interest rate sensitivity" ], "ticker": "HCA", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady execution with moderate upside as expected.", "target_price": 550 }, "bear": { "prob": 0.3, "notes": "Regulatory headwinds and slower growth materialize.", "target_price": 480 }, "bull": { "prob": 0.2, "notes": "Strong operational improvements drive market share gains.", "target_price": 600 } }, "confidence": 0.65, "assumptions": { "wacc": 0.08, "revenue_cagr_3y": 0.07, "terminal_multiple": 11, "ebit_margin_target": 0.18 }, "key_drivers": [ { "driver": "EPS Growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Revenue Growth", "impact": "MED", "direction": "POS" }, { "driver": "Healthcare Demand", "impact": "HIGH", "direction": "POS" }, { "driver": "Regulatory Changes", "impact": "HIGH", "direction": "NEG" }, { "driver": "Debt Levels", "impact": "MED", "direction": "NEG" }, { "driver": "Operational Efficiency", "impact": "HIGH", "direction": "POS" }, { "driver": "Competition", "impact": "MED", "direction": "NEG" }, { "driver": "Economic Conditions", "impact": "LOW", "direction": "NEG" } ], "method_notes": "DCF and multiples analysis using historical data. BUY due to 9% 12M expected return with balanced risks. Not investment advice.", "current_price": 505.12, "recommendation": "BUY", "thesis_bullets": [ "Strong EPS growth from operational efficiencies.", "Stable healthcare demand supports revenue growth.", "Low PEG ratio indicates attractive valuation.", "High debt offset by robust cash flow generation.", "Regulatory risks mitigated by strong market position." ], "target_price_6m": 520, "target_price_12m": 550 }, "errorsJson": { "attempts": [], "providerMeta": { "endpoint": "https://api.deepseek.com/v1/chat/completions", "provider": "deepseek", "webSearch": { "enabled": false, "supported": false }, "responseFormat": "json_object" }, "sanityIssues": [] }, "latencyMs": 336, "createdAt": "2026-04-09T05:20:58.623Z", "usage": { "inputTokens": 2194, "outputTokens": 2933, "costUsd": 0.001846 } }, { "id": "cmnr141dy046bp658iatzs2ad", "runId": "cmnr141du0466p6583cym5l7c", "modelId": "gemini.3-pro", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Equity Research AI - Healthcare Sector\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"HCA\",\n \"currency\": \"USD\",\n \"current_price\": 505.12,\n \"target_price_6m\": 545.0,\n \"target_price_12m\": 585.0,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.7,\n \"thesis_bullets\": [\n \"Dominant market share in high-growth geographic regions like Florida and Texas.\",\n \"Strong operating leverage driven by high-acuity service lines and scale.\",\n \"Effective management of labor costs through internal staffing agencies.\",\n \"Consistent capital return via aggressive share buybacks and dividends.\",\n \"Favorable demographic trends supporting long-term inpatient and outpatient demand.\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Same-facility admission growth\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Managed care pricing resets\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Nursing labor cost inflation\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Case mix index and acuity levels\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Share repurchase execution\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Medicare reimbursement updates\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Shortage of specialized nursing staff increasing contract labor reliance.\",\n \"Legislative changes to the Affordable Care Act or Medicaid funding.\",\n \"Economic downturn reducing elective procedure volumes.\",\n \"High leverage ratio relative to peers in rising rate environment.\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.065,\n \"ebit_margin_target\": 0.145,\n \"wacc\": 0.085,\n \"terminal_multiple\": 11.5\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 440.0,\n \"prob\": 0.2,\n \"notes\": \"Significant labor cost spike and reimbursement cuts.\"\n },\n \"base\": {\n \"target_price\": 585.0,\n \"prob\": 0.55,\n \"notes\": \"Steady volume growth and stable margins.\"\n },\n \"bull\": {\n \"target_price\": 640.0,\n \"prob\": 0.25,\n \"notes\": \"Accelerated market share gains and lower contract labor.\"\n }\n },\n \"method_notes\": \"Valuation utilizes a blended EV/EBITDA and P/E approach. Target reflects 11.5x forward EBITDA, consistent with historical premium for scale and operational efficiency. BUY rating supported by ~16% total return potential. Not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "Equity Research AI - Healthcare Sector", "risks": [ "Shortage of specialized nursing staff increasing contract labor reliance.", "Legislative changes to the Affordable Care Act or Medicaid funding.", "Economic downturn reducing elective procedure volumes.", "High leverage ratio relative to peers in rising rate environment." ], "ticker": "HCA", "currency": "USD", "scenarios": { "base": { "prob": 0.55, "notes": "Steady volume growth and stable margins.", "target_price": 585 }, "bear": { "prob": 0.2, "notes": "Significant labor cost spike and reimbursement cuts.", "target_price": 440 }, "bull": { "prob": 0.25, "notes": "Accelerated market share gains and lower contract labor.", "target_price": 640 } }, "confidence": 0.7, "assumptions": { "wacc": 0.085, "revenue_cagr_3y": 0.065, "terminal_multiple": 11.5, "ebit_margin_target": 0.145 }, "key_drivers": [ { "driver": "Same-facility admission growth", "impact": "HIGH", "direction": "POS" }, { "driver": "Managed care pricing resets", "impact": "HIGH", "direction": "POS" }, { "driver": "Nursing labor cost inflation", "impact": "HIGH", "direction": "NEG" }, { "driver": "Case mix index and acuity levels", "impact": "MED", "direction": "POS" }, { "driver": "Share repurchase execution", "impact": "MED", "direction": "POS" }, { "driver": "Medicare reimbursement updates", "impact": "HIGH", "direction": "NEG" } ], "method_notes": "Valuation utilizes a blended EV/EBITDA and P/E approach. Target reflects 11.5x forward EBITDA, consistent with historical premium for scale and operational efficiency. BUY rating supported by ~16% total return potential. Not investment advice.", "current_price": 505.12, "recommendation": "BUY", "thesis_bullets": [ "Dominant market share in high-growth geographic regions like Florida and Texas.", "Strong operating leverage driven by high-acuity service lines and scale.", "Effective management of labor costs through internal staffing agencies.", "Consistent capital return via aggressive share buybacks and dividends.", "Favorable demographic trends supporting long-term inpatient and outpatient demand." ], "target_price_6m": 545, "target_price_12m": 585 }, "errorsJson": { "attempts": [], "providerMeta": { "model": "gemini-3-flash-preview", "provider": "gemini", "webSearch": { "used": false, "allowed": false, "enabled": false, "requested": false, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 13583, "createdAt": "2026-04-09T05:20:58.623Z", "usage": { "inputTokens": 2557, "outputTokens": 783, "costUsd": 0.01451 } }, { "id": "cmnr141dy0469p658dtn3yibf", "runId": "cmnr141du0466p6583cym5l7c", "modelId": "openai.gpt-5.4", "status": "SUCCESS", "rawOutput": "{\"model\":\"OpenAI Equity Research Model v2\",\"as_of\":\"2026-04-08T20:00:02.000Z\",\"ticker\":\"HCA\",\"currency\":\"USD\",\"current_price\":505.12,\"target_price_6m\":536,\"target_price_12m\":555,\"recommendation\":\"BUY\",\"confidence\":0.66,\"thesis_bullets\":[\"Stable inpatient demand and acuity support steady same-facility revenue growth.\",\"Labor normalization and scale sustain margin resilience versus peers.\",\"Strong FCF funds buybacks, reducing share count and boosting EPS.\",\"Valuation near 15-16x forward earnings looks reasonable, not stretched.\",\"High leverage and policy reimbursement risk cap multiple expansion.\"],\"key_drivers\":[{\"driver\":\"Admissions and acuity mix\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Commercial pricing\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Labor cost normalization\",\"impact\":\"HIGH\",\"direction\":\"POS\"},{\"driver\":\"Medicare/Medicaid reimbursement pressure\",\"impact\":\"HIGH\",\"direction\":\"NEG\"},{\"driver\":\"Share repurchases\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Interest expense and leverage\",\"impact\":\"MED\",\"direction\":\"NEG\"},{\"driver\":\"Outpatient network growth\",\"impact\":\"MED\",\"direction\":\"POS\"},{\"driver\":\"Regulatory/legal matters\",\"impact\":\"MED\",\"direction\":\"NEG\"}],\"risks\":[\"Reimbursement cuts or slower commercial pricing\",\"Wage inflation and staffing shortages\",\"Volume softness from weaker acuity or utilization\",\"Higher malpractice or regulatory settlements\",\"Leverage limits capital flexibility\"],\"assumptions\":{\"revenue_cagr_3y\":5.5,\"ebit_margin_target\":15.8,\"wacc\":8.4,\"terminal_multiple\":16.8},\"scenarios\":{\"bear\":{\"target_price\":430,\"prob\":0.25,\"notes\":\"Margins compress and reimbursement or labor headwinds limit EPS growth.\"},\"base\":{\"target_price\":555,\"prob\":0.5,\"notes\":\"Mid-single-digit revenue growth and buybacks support modest multiple expansion.\"},\"bull\":{\"target_price\":635,\"prob\":0.25,\"notes\":\"Volumes, pricing, and labor trends stay favorable, driving stronger EPS.\"}},\"method_notes\":\"12M target uses a blended forward earnings and cash-flow framework anchored to snapshot fundamentals, with multiple cross-checks versus FCF yield and leverage. Snapshot quote fields were not overridden. No sell-side targets used as inputs. not investment advice\"}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "OpenAI Equity Research Model v2", "risks": [ "Reimbursement cuts or slower commercial pricing", "Wage inflation and staffing shortages", "Volume softness from weaker acuity or utilization", "Higher malpractice or regulatory settlements", "Leverage limits capital flexibility" ], "ticker": "HCA", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Mid-single-digit revenue growth and buybacks support modest multiple expansion.", "target_price": 555 }, "bear": { "prob": 0.25, "notes": "Margins compress and reimbursement or labor headwinds limit EPS growth.", "target_price": 430 }, "bull": { "prob": 0.25, "notes": "Volumes, pricing, and labor trends stay favorable, driving stronger EPS.", "target_price": 635 } }, "confidence": 0.66, "assumptions": { "wacc": 8.4, "revenue_cagr_3y": 5.5, "terminal_multiple": 16.8, "ebit_margin_target": 15.8 }, "key_drivers": [ { "driver": "Admissions and acuity mix", "impact": "HIGH", "direction": "POS" }, { "driver": "Commercial pricing", "impact": "HIGH", "direction": "POS" }, { "driver": "Labor cost normalization", "impact": "HIGH", "direction": "POS" }, { "driver": "Medicare/Medicaid reimbursement pressure", "impact": "HIGH", "direction": "NEG" }, { "driver": "Share repurchases", "impact": "MED", "direction": "POS" }, { "driver": "Interest expense and leverage", "impact": "MED", "direction": "NEG" }, { "driver": "Outpatient network growth", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory/legal matters", "impact": "MED", "direction": "NEG" } ], "method_notes": "12M target uses a blended forward earnings and cash-flow framework anchored to snapshot fundamentals, with multiple cross-checks versus FCF yield and leverage. Snapshot quote fields were not overridden. No sell-side targets used as inputs. not investment advice", "current_price": 505.12, "recommendation": "BUY", "thesis_bullets": [ "Stable inpatient demand and acuity support steady same-facility revenue growth.", "Labor normalization and scale sustain margin resilience versus peers.", "Strong FCF funds buybacks, reducing share count and boosting EPS.", "Valuation near 15-16x forward earnings looks reasonable, not stretched.", "High leverage and policy reimbursement risk cap multiple expansion." ], "target_price_6m": 536, "target_price_12m": 555 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "openai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "resp_06dd4ef8e12ae59f0069d759b1dae48193ab90b3186d83320f", "reasoningEffort": "medium", "structuredOutputs": { "used": true, "requested": true, "disabledReason": null } }, "sanityIssues": [] }, "latencyMs": 48253, "createdAt": "2026-04-09T05:20:58.623Z", "usage": { "inputTokens": 2464, "outputTokens": 2577, "costUsd": 0.04039 } }, { "id": "cmnr141dy046cp658czezqh06", "runId": "cmnr141du0466p6583cym5l7c", "modelId": "xai.grok-4.20-reasoning", "status": "SUCCESS", "rawOutput": "{\n \"model\": \"Integrated DCF Scenario Model\",\n \"as_of\": \"2026-04-08T20:00:02.000Z\",\n \"ticker\": \"HCA\",\n \"currency\": \"USD\",\n \"current_price\": 505.12,\n \"target_price_6m\": 530,\n \"target_price_12m\": 565,\n \"recommendation\": \"BUY\",\n \"confidence\": 0.62,\n \"thesis_bullets\": [\n \"Aging demographics drive steady inpatient volumes\",\n \"Operational efficiencies support margin stability\",\n \"Strong FCF funds debt paydown and dividends\",\n \"High leverage exposes to rising interest costs\",\n \"Reimbursement policy shifts threaten margins\"\n ],\n \"key_drivers\": [\n {\n \"driver\": \"Aging population demand\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Labor cost inflation\",\n \"impact\": \"HIGH\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Hospital utilization rates\",\n \"impact\": \"HIGH\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Medicare reimbursement changes\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"Operational efficiency gains\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Interest rate environment\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n },\n {\n \"driver\": \"M&A integration success\",\n \"impact\": \"MED\",\n \"direction\": \"POS\"\n },\n {\n \"driver\": \"Regulatory scrutiny\",\n \"impact\": \"MED\",\n \"direction\": \"NEG\"\n }\n ],\n \"risks\": [\n \"Medicare rate cuts\",\n \"Labor wage pressures\",\n \"High debt burden\",\n \"Litigation and compliance\",\n \"Economic slowdown in electives\"\n ],\n \"assumptions\": {\n \"revenue_cagr_3y\": 0.065,\n \"ebit_margin_target\": 0.175,\n \"wacc\": 0.082,\n \"terminal_multiple\": 11.5\n },\n \"scenarios\": {\n \"bear\": {\n \"target_price\": 430,\n \"prob\": 0.25,\n \"notes\": \"Regulatory cuts and cost inflation erode margins.\"\n },\n \"base\": {\n \"target_price\": 565,\n \"prob\": 0.5,\n \"notes\": \"Steady volume growth and efficiency gains continue.\"\n },\n \"bull\": {\n \"target_price\": 645,\n \"prob\": 0.25,\n \"notes\": \"Accelerated demand and margin expansion exceed expectations.\"\n }\n },\n \"method_notes\": \"DCF valuation using revenue CAGR, target EBIT margin, 8.2% WACC and 11.5x terminal multiple. 12M target implies ~12% upside consistent with BUY per rubric. Consensus not used as input. not investment advice.\"\n}", "parsedJson": { "as_of": "2026-04-08T20:00:02.000Z", "model": "Integrated DCF Scenario Model", "risks": [ "Medicare rate cuts", "Labor wage pressures", "High debt burden", "Litigation and compliance", "Economic slowdown in electives" ], "ticker": "HCA", "currency": "USD", "scenarios": { "base": { "prob": 0.5, "notes": "Steady volume growth and efficiency gains continue.", "target_price": 565 }, "bear": { "prob": 0.25, "notes": "Regulatory cuts and cost inflation erode margins.", "target_price": 430 }, "bull": { "prob": 0.25, "notes": "Accelerated demand and margin expansion exceed expectations.", "target_price": 645 } }, "confidence": 0.62, "assumptions": { "wacc": 0.082, "revenue_cagr_3y": 0.065, "terminal_multiple": 11.5, "ebit_margin_target": 0.175 }, "key_drivers": [ { "driver": "Aging population demand", "impact": "HIGH", "direction": "POS" }, { "driver": "Labor cost inflation", "impact": "HIGH", "direction": "NEG" }, { "driver": "Hospital utilization rates", "impact": "HIGH", "direction": "POS" }, { "driver": "Medicare reimbursement changes", "impact": "MED", "direction": "NEG" }, { "driver": "Operational efficiency gains", "impact": "MED", "direction": "POS" }, { "driver": "Interest rate environment", "impact": "MED", "direction": "NEG" }, { "driver": "M&A integration success", "impact": "MED", "direction": "POS" }, { "driver": "Regulatory scrutiny", "impact": "MED", "direction": "NEG" } ], "method_notes": "DCF valuation using revenue CAGR, target EBIT margin, 8.2% WACC and 11.5x terminal multiple. 12M target implies ~12% upside consistent with BUY per rubric. Consensus not used as input. not investment advice.", "current_price": 505.12, "recommendation": "BUY", "thesis_bullets": [ "Aging demographics drive steady inpatient volumes", "Operational efficiencies support margin stability", "Strong FCF funds debt paydown and dividends", "High leverage exposes to rising interest costs", "Reimbursement policy shifts threaten margins" ], "target_price_6m": 530, "target_price_12m": 565 }, "errorsJson": { "attempts": [], "providerMeta": { "provider": "xai", "webSearch": { "used": false, "enabled": false, "sources": [], "maxToolCalls": 2 }, "responseId": "a16273a7-f6d4-988c-8e21-c7774003aebc", "usedFallbackChatCompletions": false }, "sanityIssues": [] }, "latencyMs": 14613, "createdAt": "2026-04-09T05:20:58.623Z", "usage": { "inputTokens": 2803, "outputTokens": 2536, "costUsd": 0.046449 } } ] } }